In this context, it is notable that antidiabetic drugs such as thiazolidinediones, which are PPARγ agonists used to treat insulin resistance, can activate PXR, potentially causing adverse metabolic effects or insulin resistance via interfering with PPARγ signaling [27]. Here, NR1I2 is linked to Insulin resistance.